Member Terri Shieh-Newton spoke to Managing IP about the potential rise of biosimilar patent litigation in the U.S. Terri said, "The board can be a good resource for biosimilar companies because administrative patent judges have scientific backgrounds and there's a lower threshold for proving invalidity."
SOURCE